Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099763 | 0.89 | DEGS1 (0.39) | SSTR3DRD4SLC6A12SLC6A13 | |
| SCHEMBL6099482 | 0.88 | F10 (0.45) | SSTR3DRD4SLC6A12SLC6A13 | |
| SCHEMBL6098763 | 0.87 | SMYD3 (0.52) | DRD4 | |
| SCHEMBL6101158 | 0.85 | NPC1 (0.49) | DRD4SLC6A12SLC6A13 | |
| SCHEMBL6099327 | 0.85 | EPHX2 (0.45) | SSTR3 | |
| SCHEMBL6099794 | 0.85 | SSTR3 (0.36) | SSTR3DRD4SLC6A12SLC6A13 | |
| SCHEMBL6480026 | 0.84 | CHRNA7 (0.58) | — | |
| SCHEMBL6098549 | 0.83 | HTR3A (0.60) | — | |
| SCHEMBL6099232 | 0.83 | SSTR3 (0.41) | SSTR3DRD4SLC6A12SLC6A13 | |
| SCHEMBL6099712 | 0.83 | SSTR3 (0.41) | SSTR3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | SSTR3 463/4885DRD4 2751/4885SLC6A12 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.